Results 171 to 180 of about 784,373 (290)
«METHOTREXATE ERA» IN CHILDREN RHEUMATOLOGY
Вопросы современной педиатрии, 2006 This article sites modern principles and theoretical substantiation of pharmacotherapy by methotrexate in patients with juvenile arthritis. Particular emphasis has been placed on parenter al methods of drug introduction, as the possibility of therapy ...
S.R. Rodionovskaya, I.P. Nikishina
doaj
Arthritis &Rheumatology, Volume 77, Issue 10, Page 1442-1450, October 2025.Objective Systemic juvenile idiopathic arthritis (sJIA) is a chronic childhood disease classically attributed to innate immune cell dysregulation. This study aimed to elucidate the role of innate lymphoid cells (ILCs), including natural killer (NK) cells and helper‐ILCs (hILCs), in sJIA during clinically inactive disease (CID) through phenotypic and ...
Linda Quatrini +19 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 91, Issue 10, Page 2854-2864, October 2025.Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza +26 more
wiley +1 more source
Вопросы современной педиатрии, 2011 This article contains observation of severe poliarticular variant of juvenile rheumatoid arthritis, resistant to glucocorticoid treatment and classic immunosuppressive therapy.
T.V. Sleptsova +5 more
doaj
Juvenile rheumatoid arthritis (Juvenile chronic arthritis)
Dermatology Online Journal, 2001 openaire +4 more sources
Immune‐Mediated Necrotizing Myopathy Diagnosis and Flare in an Adolescent After COVID‐19 Vaccine
Clinical Case Reports, Volume 13, Issue 10, October 2025.Muscle biopsy is histopathologically consistent with a diagnosis of immune‐mediated necrotizing myopathy. ABSTRACT We discuss a teenager who developed a rare pediatric autoimmune muscle disease after completing the primary COVID‐19 vaccine series, which flared shortly after COVID‐19 booster vaccination.
Patricia Hoffman +3 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 917-927, October 2025.Tocilizumab dosing for management of T cell‐engaging bispecific antibody‐related CRS in patients with R/R B‐cell NHL. The recent surge in T‐cell‐engaging and chimeric antigen receptor (CAR) T‐cell therapies is changing the landscape of cancer therapy.
Candice Jamois +13 more
wiley +1 more source
Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Diabetes/Metabolism Research and Reviews, Volume 41, Issue 7, October 2025.While disease‐modifying therapies (DMTs) have been used to treat autoimmune diseases for decades, until recently, DMTs had not been used to treat autoimmune type 1 diabetes (T1D). The approval of the first DMT for use in individuals with preclinical T1D, teplizumab, has ushered in a new era in which healthcare providers can slow the T1D disease course.
Aaron W. Michels +3 more
wiley +1 more source
Epilepsy and systemic autoimmune diseases: A bidirectional two‐sample Mendelian randomization study
Epilepsia Open, Volume 10, Issue 5, Page 1415-1425, October 2025.Abstract Objective Epidemiological data indicates that individuals with epilepsy exhibit an elevated susceptibility to autoimmune disorders, and conversely, those with systemic autoimmune diseases (SAD) demonstrate a heightened predisposition to epilepsy.
Ruoshi Tian +4 more
wiley +1 more source
Physical activity and quality of life of children and adolescents with juvenile idiopathic arthritis, juvenile systemic lupus erythematosus and juvenile dermatomyositis during the COVID-19 pandemic. [PDF]
J Pediatr (Rio J)Soares R +5 more
europepmc +1 more source